Pulse pressure has recently emerged as a strong independent predictor of cardiovascular events in the general population and in essential hypertension (EH). Therefore, pulse pressure reduction may represent an important new therapeutic goal in EH. Basic research suggests a favorable effect of natriuretic peptides on conduit vessels. Therefore, we assessed changes in peripheral (PPP) and central (CPP) pulse pressure and conduit vessel stiffness in a 12-week double blind, randomized clinical trial that compared the monotherapeutic effects of angiotensin converting enzyme (ACE) inhibition with enalapril (Nϭ87) versus vasopeptidase (dual ACE plus neutral endopeptidase) inhibition with omapatrilat (Nϭ80). Patients were withdrawn from standard antihypertensive medication for 1-2 weeks prior to enrollment and systolic pressure was confirmed to be Ն160 mmHg. Using calibrated tonometry and pulsed Doppler, pulsatile hemodynamics were assessed prior to randomization and 24 hours after last dose of study medication. Omapatrilat produced greater reductions in PPP, CPP and characteristic impedance (Zc), which is a direct measure of the stiffness of the central aorta. The differential change in Zc remained significant (P Ͻ 0.05) after adjusting for baseline Zc, baseline mean pressure and change in mean pressure.
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Vasopeptidase inhibition with omapatrilat, as compared to converting enzyme inhibition with enalapril, produced greater reductions in peripheral and central pulse pressure in association with a pressure-independent reduction in proximal aortic stiffness (Zc). These findings are consistent with a favorable effect of natriuretic peptides on central conduit vessel function. Objective: BLD Todays guidelines for antihypertensive therapy in acute ischemic stroke suggest to reduce BP values of over 220 mmHg systolic (AHA) or 200/110 mmHg (german hypertension society). No intervention trials have so far evaluated an immediate BP reduction on the clinical outcome of the pts neurological status (morbidity) or mortality rates in the acute stroke situation. However, some studies show an increase in mortality after a quick BP reduction in a short time interval. The influence of an early, moderate BP reduction with Candesartan cilexetil in patients with acute cerebral ischemia was compared with restrictive antihypertensive therapy in the ACCESS-trial.
Design: Patients with acute cerebral ischemia and neurological deficit and initial BP values of Ͼ200/110 mmHg (systolic and / or diastolic) in occasinal BP measuring or Ͼ 180/105 mmHg as median value of two measurements in 30 minutes were randomized. Furthermore a motor paresis had to be present. Patients were treated randomised double-blind for 7 days with placebo or the AT-1-receptor antagonist Candesartan cilexetil. On the 5-7th day all pts got an ABPM.
All hypertensive patients from both groups had been treated with Candesartan if they were hypertensive in the ABPM. Normotensive patients were followed-up, but not treated. If hypertension remained, a combination therapy with other antihypertensive agents was possible. Primary endpoints were the patients morbidity (functional status measured with Rankin and Barthel index, degree of motor deficit by NIHscale), and mortality rates after 3 months. Follow up was continued for 12 months.
Results: BLD Inclusion of patients was stopped because of ethical reasons. 
